← All indications
Neurofibromatosis 2
An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.
Drugs by status
Phase 3 trials (1)
Phase 2 trials (14)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 2 Indications (22)
- Takeda
- AstraZeneca
- Genentech
- Novartis
- Betta Pharmaceuticals Co.,Ltd.
- GlaxoSmithKline
- PTC Therapeutics
- Simcere Pharmaceutical Co., Ltd
- National Cancer Institute (NCI)
- Beijing Tiantan Hospital
- Harvard University
- Johns Hopkins University
- New York University
- Northwestern University
- Capital Medical University
- University of California, Los Angeles
- University of Cincinnati
- Department of Defense
- University of Alabama, Birmingham
- University of Paris
- The Children's Tumor Foundation
- Memorial Sloan-Kettering Cancer Center
Organization Involved with Phase 1 Indications (7)